# Response to Objectives

Generated: 2026-03-24 15:06 UTC

---

This document maps the pipeline outputs to each of the 37 stated objectives.

## Objective 1

> **Demographics**: age at diagnosis (months), sex, weight

**Addressed by pipeline findings:**

- Median age (months): 30.0
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 2

> **Disease staging**: INRG stage (1, 2A, 2B, 3, 4, 4S), risk group (low / intermediate / high)

**Addressed by pipeline findings:**

- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 3

> **Molecular markers**: MYCN amplification, ploidy, del(1p), gain(17q), 11q aberration, segmental chromosomal aberrations (SCA)

**Addressed by pipeline findings:**

- *(Insight)* Risk x MYCN event-rate cells can guide stratified hypothesis tests and sample-size planning for future validation.

## Objective 4

> **Histology**: favorable / unfavorable

**Status:** No direct match found in current report/insights — further analysis may be required.

## Objective 5

> **Serum biomarkers**: LDH (IU/L), ferritin (ng/mL), NSE (ng/mL)

**Status:** No direct match found in current report/insights — further analysis may be required.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`

## Objective 6

> **Treatment**: observation, induction chemotherapy, surgery only

**Status:** No direct match found in current report/insights — further analysis may be required.

## Objective 7

> **Treatment response**: CR, PR, MR, NR, PD

**Status:** No direct match found in current report/insights — further analysis may be required.

## Objective 8

> **Gene expression (log2)**: MYCN, ALK, PHOX2B, TH, CHGB, DBH, NTRK1, NTRK2, MDM2, CDK4, BIRC5, CCND1, MYC, TERT, ATRX, TP53, CDK6, CDKN2A, RB1, VEGF, HIF1A, HAND2, ID2, FOXO1

**Addressed by pipeline findings:**

- *(Insight)* Risk x MYCN event-rate cells can guide stratified hypothesis tests and sample-size planning for future validation.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`

## Objective 9

> **Outcomes**: event-free survival (EFS, months), overall survival (OS, months), event flags

**Addressed by pipeline findings:**

- *(Insight)* Overall event rate: 48.75%
- *(Insight)* Curve separation can be translated into formal survival modeling hypotheses with adjusted covariates.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_event_rate_heatmap.png`
- `survival_km_by_mycn.png`

## Objective 10

> **O1.1** Generate Kaplan-Meier curves for EFS and OS stratified by risk group (low / intermediate / high).

**Addressed by pipeline findings:**

- expr_mycn: correlation with EFS = -0.306
- expr_tert: correlation with EFS = -0.288
- expr_hand2: correlation with EFS = 0.239
- *(Insight)* Median EFS (months): 30.1
- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_event_rate_heatmap.png`
- `survival_km_by_mycn.png`

## Objective 11

> **O1.2** Compare OS and EFS between MYCN-amplified and non-amplified patients using log-rank tests.

**Addressed by pipeline findings:**

- expr_mycn: correlation with EFS = -0.306
- expr_tert: correlation with EFS = -0.288
- expr_hand2: correlation with EFS = 0.239
- *(Insight)* Median EFS (months): 30.1
- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.

**Related charts:**

- `clinical_efs_by_risk.png`
- `survival_event_rate_heatmap.png`
- `survival_km_by_mycn.png`
- `survival_km_by_risk.png`

## Objective 12

> **O1.3** Perform multivariate Cox proportional-hazards regression for OS including stage, risk group, MYCN amplification, ploidy, histology, LDH, ferritin, and NSE as covariates.

**Addressed by pipeline findings:**

- This report is exploratory and non-causal; observed associations should not be interpreted as treatment effects.
- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 13

> **O1.4** Determine 3-year and 5-year OS and EFS rates per disease stage.

**Addressed by pipeline findings:**

- expr_mycn: correlation with EFS = -0.306
- expr_tert: correlation with EFS = -0.288
- expr_hand2: correlation with EFS = 0.239
- *(Insight)* Median EFS (months): 30.1
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 14

> **O1.5** Assess whether age at diagnosis (< 18 months vs. ≥ 18 months) is an independent prognostic factor for EFS.

**Addressed by pipeline findings:**

- Median age (months): 30.0
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 15

> **O2.1** Evaluate whether elevated LDH (above median) at diagnosis is associated with worse OS.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

## Objective 16

> **O2.2** Correlate serum ferritin levels with disease stage and risk group.

**Addressed by pipeline findings:**

- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 17

> **O2.3** Determine the optimal NSE cut-off for discriminating high-risk from non-high-risk patients (ROC / AUC analysis).

**Addressed by pipeline findings:**

- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_km_by_risk.png`

## Objective 18

> **O2.4** Assess whether the combination of LDH + ferritin + NSE improves prognostic classification over any single marker alone.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

## Objective 19

> **O3.1** Quantify the co-occurrence of MYCN amplification with del(1p), gain(17q), and 11q aberration.

**Addressed by pipeline findings:**

- *(Insight)* Risk x MYCN event-rate cells can guide stratified hypothesis tests and sample-size planning for future validation.

## Objective 20

> **O3.2** Determine whether segmental chromosomal aberrations (SCA) independently predict outcome when controlling for MYCN status.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_km_by_risk.png`

## Objective 21

> **O3.3** Compare EFS distributions across ploidy groups (diploid, near-triploid, hyperdiploid).

**Addressed by pipeline findings:**

- expr_mycn: correlation with EFS = -0.306
- expr_tert: correlation with EFS = -0.288
- expr_hand2: correlation with EFS = 0.239
- *(Insight)* Median EFS (months): 30.1
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 22

> **O3.4** Identify which combination of genomic markers (MYCN, del_1p, gain_17q, aberration_11q, ploidy) best stratifies patients into distinct survival clusters.

**Addressed by pipeline findings:**

- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.
- *(Insight)* The survival-style curves illustrate time-to-event separation across groups and help identify clinically distinct trajectories.

**Related charts:**

- `clinical_efs_by_risk.png`
- `survival_event_rate_heatmap.png`
- `survival_km_by_mycn.png`
- `survival_km_by_risk.png`

## Objective 23

> **O4.1** Identify gene expression features (from the 24 profiled genes) that are significantly differentially expressed between MYCN-amplified and non-amplified tumors (t-test / Mann-Whitney, FDR-corrected).

**Addressed by pipeline findings:**

- *(Insight)* The survival-style curves illustrate time-to-event separation across groups and help identify clinically distinct trajectories.
- *(Insight)* The survival-style curves illustrate time-to-event separation across groups and help identify clinically distinct trajectories.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`

## Objective 24

> **O4.2** Determine whether high TERT expression is associated with shorter EFS independent of MYCN amplification.

**Addressed by pipeline findings:**

- expr_mycn: correlation with EFS = -0.306
- expr_tert: correlation with EFS = -0.288
- expr_hand2: correlation with EFS = 0.239
- *(Insight)* Median EFS (months): 30.1
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`
- `clinical_efs_by_risk.png`

## Objective 25

> **O4.3** Correlate NTRK1 and NTRK2 expression levels with histological classification (favorable vs. unfavorable) and with EFS.

**Status:** No direct match found in current report/insights — further analysis may be required.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`
- `clinical_efs_by_risk.png`

## Objective 26

> **O4.4** Assess whether ATRX expression differs significantly across ploidy groups.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`

## Objective 27

> **O4.5** Build a gene expression signature (from the 24 genes) that predicts treatment response category (CR/PR vs. MR/NR/PD) using logistic regression or random forest.

**Addressed by pipeline findings:**

- This report is exploratory and non-causal; observed associations should not be interpreted as treatment effects.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`

## Objective 28

> **O4.6** Cluster patients by gene expression profile (unsupervised hierarchical clustering or k-means) and test whether the resulting clusters align with established risk groups.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`
- `clinical_efs_by_risk.png`

## Objective 29

> **O5.1** Identify pre-treatment clinical and molecular variables (stage, risk group, MYCN, biomarkers) that are the strongest predictors of complete response (CR).

**Addressed by pipeline findings:**

- *(Insight)* This figure provides exploratory clinical context for cohort phenotype and outcomes.
- *(Insight)* This figure provides exploratory clinical context for cohort phenotype and outcomes.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`
- `clinical_age_distribution.png`

## Objective 30

> **O5.2** Compare response rates (CR vs. non-CR) between treatment modalities (observation, induction chemotherapy, surgery only).

**Addressed by pipeline findings:**

- This report is exploratory and non-causal; observed associations should not be interpreted as treatment effects.

## Objective 31

> **O5.3** Determine whether gene expression of VEGF and HIF1A predicts response to induction chemotherapy.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`

## Objective 32

> **O5.4** Build a multivariate model to predict progressive disease (PD) as an outcome; report sensitivity, specificity, and AUC.

**Addressed by pipeline findings:**

- This report is exploratory and non-causal; observed associations should not be interpreted as treatment effects.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_km_by_risk.png`

## Objective 33

> **O6.1** Compare OS between male and female patients within each risk group.

**Addressed by pipeline findings:**

- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_km_by_risk.png`

## Objective 34

> **O6.2** Characterise the stage 4S subgroup: distribution of molecular markers, response rates, and OS vs. other stage 4 patients.

**Addressed by pipeline findings:**

- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 35

> **O6.3** Assess whether weight at diagnosis (as a proxy for nutritional/physiological status) correlates with any clinical or molecular variable.

**Addressed by pipeline findings:**

- *(Insight)* This figure provides exploratory clinical context for cohort phenotype and outcomes.
- *(Insight)* Age distribution informs external validity and whether age-adjusted analyses are needed.

**Related charts:**

- `clinical_age_distribution.png`
- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `clinical_stage_distribution.png`

## Objective 36

> **O7.1** Construct a composite prognostic score integrating clinical (stage, age), molecular (MYCN, SCA, ploidy), and gene expression features; validate using leave-one-out cross-validation.

**Addressed by pipeline findings:**

- *(Insight)* This figure provides exploratory clinical context for cohort phenotype and outcomes.
- *(Insight)* This figure provides exploratory clinical context for cohort phenotype and outcomes.

**Related charts:**

- `biomarker_correlation_heatmap.png`
- `biomarker_expression_summary.png`
- `biomarker_mycn_vs_alk.png`
- `clinical_age_distribution.png`

## Objective 37

> **O7.2** Compare the discriminative power (C-index) of the new composite score vs. the current INRG risk classification for predicting 5-year OS.

**Addressed by pipeline findings:**

- *(Insight)* The cohort is dominated by 'high' risk patients (198 cases), which can influence aggregate outcome interpretation.
- *(Insight)* Median EFS differs across risk strata, with high showing the lowest and low the highest median in this sample.

**Related charts:**

- `clinical_efs_by_risk.png`
- `clinical_risk_distribution.png`
- `survival_km_by_risk.png`

---

## Pipeline Output Summary

- Charts generated: 12
- Report available: Yes
- Insights available: Yes
- Objectives stated: 37

## Caveats

- Objective matching is keyword-based and exploratory.
- All findings are non-causal and should be validated in an independent cohort.
- This response was generated automatically from pipeline outputs.
